Callan Family Office’s GSK GSK Stock Holding History

Callan Family Office’s Portfolio GSK Stock Details GSK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$14.2M	Sell	271,081 -10,594	-4%	-$560K	0.28%	68
2026 Q1	$15.5M	Sell	281,675 -4,254	-1%	-$231K	0.35%	52
2025 Q4	$14M	Buy	285,929 +66,376	+30%	+$3.1M	0.3%	61
2025 Q3	$9.48M	Sell	219,553 -3,866	-2%	-$151K	0.3%	66
2025 Q2	$8.58M	Buy	223,419 +156,628	+235%	+$5.98M	0.27%	75
2025 Q1	$2.59M	Buy	66,791 +9,079	+16%	+$332K	0.19%	110
2024 Q4	$1.95M	Buy	+57,712	New	+$2.08M	0.12%	156
2023 Q2	–	Sell	-25,900	Closed	-$922K	–	132
2023 Q1	$922K	Buy	+25,900	New	+$906K	0.22%	64

Other funds holding GSK

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JEST

JTC Employer Solutions Trustee St Helier, Jersey $1.25B AUM 41.83% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Callan Family Office's GSK Position: Q2 2026 in Review

Callan Family Office reduced its GSK (GSK) stake by 3.8% in Q2 2026, selling an estimated $560K and leaving 271,081 shares worth $14.2M. The position accounts for 0.28% of the portfolio, ranked #68.

Callan Family Office first reported a position in GSK in Q1 2023 and has held it in 8 quarters since. The position peaked at $15.5M in Q1 2026. 1,045 funds tracked by Wall St. Rank hold GSK as of Q2 2026.

Callan Family Office held 271,081 shares of GSK worth $14.2M as of Q2 2026.
Callan Family Office sold 10,594 GSK shares in Q2 2026, an estimated $560K.
GSK made up 0.28% of Callan Family Office's portfolio in Q2 2026, its #68 holding.
Callan Family Office first reported a position in GSK in Q1 2023 and has held it in 8 quarters since.
Callan Family Office's GSK position peaked at $15.5M in Q1 2026.
1,045 funds tracked by Wall St. Rank held GSK as of Q2 2026.

Based on Callan Family Office's 13F filing for Q2 2026, filed 11 Aug 2026.